Publications
Detailed Information
Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin
Cited 15 time in
Web of Science
Cited 18 time in Scopus
- Authors
- Issue Date
- 2005-02-19
- Publisher
- John Wiley & Sons
- Citation
- Head Neck. 2005 Apr;27(4):326-32.
- Keywords
- Animals ; Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use ; Carcinoma/pathology/*prevention & control ; Carcinoma, Squamous Cell/pathology/*prevention & control ; Cell Line, Tumor ; Cyclooxygenase 2 ; Cyclooxygenase 2 Inhibitors ; Cyclooxygenase Inhibitors/*therapeutic use ; Disease Models, Animal ; Indomethacin/*therapeutic use ; Male ; Melanoma/pathology/*prevention & control ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C3H ; Mice, Inbred C57BL ; Mice, Inbred Strains ; Muscle, Skeletal/*surgery ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Seeding ; Neoplasm Transplantation ; Peroxidases/antagonists & inhibitors ; Prostaglandin-Endoperoxide Synthases/drug effects ; Pyrazoles/*therapeutic use ; Sulfonamides/*therapeutic use
- Abstract
- BACKGROUND: Tumor growth is accelerated in surgical wounds. However, few experiments seeking to prevent such accelerated tumor growth have been performed. METHODS: We created surgical wounds in three syngeneic mice for the implantation of three murine cancer cell lines, SCC VII, CT-26, and B16F10. The tumor growth in the wound group was compared with that in non-wound-control mice. Celecoxib or indomethacin was administered to the mice that had tumor implanted into the surgical wound to observe the tumor-suppressive effect. RESULTS: The surgical wounds promoted tumor growth with different degrees, depending on the type of tumor. Such an accelerated tumor growth did not seem to be affected by cyclooxygenase-2 expression of tumors per se, but its mechanism needs to be explained by further studies. Celecoxib and indomethacin had a significant inhibitory effect on the tumor growth in the surgical wound. This suppressive effect is most obvious when celecoxib is administered daily from 1 day before surgical wounding and tumor implantation. CONCLUSION: Our results can justify that the preventive use of celecoxib in patients in whom local recurrence by tumor contamination is predicted.
- ISSN
- 1043-3074 (Print)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15719392
https://hdl.handle.net/10371/15210
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.